J. Salem, P. Sabouret, C. Funck-brentano, and J. Hulot, Pharmacology and mechanisms of action of new oral anticoagulants, Fundam Clin Pharmacol, vol.29, pp.10-20, 2015.

. Bayer, Xarelto® (rivaroxaban) Summary of Product characteristics, Pharma AG), 2019.

R. Kremers, T. C. Peters, R. J. Wagenvoord, and H. C. Hemker, The balance of pro-and anticoagulant processes underlying thrombin generation, J Thromb Haemost, vol.13, pp.437-484, 2015.

R. C. Gosselin, D. M. Adcock, S. M. Bates, J. Douxfils, E. J. Favaloro et al., International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants, Thromb Haemost, vol.118, pp.437-50, 2018.

D. Kubitza, M. Becka, B. Voith, M. Zuehlsdorf, and G. Wensing, Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor, Clin Pharmacol Ther, vol.78, pp.412-433, 2005.

W. Mueck, L. C. Borris, O. E. Dahl, S. Haas, M. V. Huisman et al., Population pharmacokinetics and pharmacodynamics of once-and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement, Thromb Haemost, vol.100, pp.453-61, 2008.

W. Mueck, B. I. Eriksson, K. A. Bauer, L. Borris, O. E. Dahl et al., Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery, Clin Pharmacokinet, vol.47, pp.203-219, 2008.

D. Kubitza, M. Becka, A. Roth, and W. Mueck, The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct Factor Xa inhibitor, J Clin Pharmacol, vol.53, pp.249-55, 2013.

W. Mueck, S. Schwers, and J. Stampfuss, Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring, Thromb J, vol.11, p.10, 2013.

I. Y. Gong and R. B. Kim, Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban, Can J Cardiol, vol.29, pp.24-33, 2013.

W. Mueck, J. Stampfuss, D. Kubitza, and M. Becka, Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban, Clin Pharmacokinet, vol.53, pp.1-16, 2014.

G. Freyburger, G. Macouillard, K. Khennoufa, S. Labrouche, M. Molimard et al., Rivaroxaban and apixaban in orthopaedics: is there a difference in their plasma concentrations and anticoagulant effects?, Blood Coagul Fibrinolysis, vol.26, pp.925-958, 2015.

I. Gouin-thibault, X. Delavenne, A. Blanchard, V. Siguret, J. E. Salem et al., Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin, J Thromb Haemost JTH, vol.15, pp.273-83, 2017.

S. Testa, O. Paoletti, C. Legnani, C. Dellanoce, E. Antonucci et al., Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants, J Thromb Haemost JTH, vol.16, pp.842-850, 2018.

J. Graff, N. Von-hentig, F. Misselwitz, D. Kubitza, M. Becka et al., Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity, J Clin Pharmacol, vol.47, pp.1398-407, 2007.

P. Vranckx, F. W. Leebeek, J. G. Tijssen, J. Koolen, F. Stammen et al., Peri-procedural use of rivaroxaban in elective percutaneous coronary intervention to treat stable coronary artery disease. The X-PLORER trial, Thromb Haemost, vol.114, pp.258-67, 2015.

D. M. Siegal, J. T. Curnutte, S. J. Connolly, G. Lu, P. B. Conley et al., Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity, N Engl J Med, vol.373, pp.2413-2437, 2015.

A. E. Tsantes, E. Kyriakou, I. Ikonomidis, K. Katogiannis, I. Papadakis et al., Comparative assessment of the anticoagulant activity of rivaroxaban and dabigatran in patients with nonvalvular atrial fibrillation: a noninterventional study, Medicine (Baltimore), vol.95, p.3037, 2016.

R. Artang, M. Anderson, P. Riley, and J. D. Nielsen, Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay, Res Pract Thromb Haemost, vol.1, pp.194-201, 2017.

R. Kreutz, P. B. Persson, D. Kubitza, K. Thelen, S. Heitmeier et al., Dissociation between the pharmacokinetics and pharmacodynamics of oncedaily rivaroxaban and twice-daily apixaban: a randomized crossover study, J Thromb Haemost, vol.15, pp.2017-2045, 2017.

T. A. Helin, L. Virtanen, M. Manninen, J. Leskinen, J. Leppilahti et al., Effects of thromboprophylactic doses of apixaban and rivaroxaban on coagulation and thrombin generation in association with total hip replacement, J Thromb Thrombolysis, vol.43, pp.562-571, 2017.

D. Bertaggia-calderara, D. Kröll, C. Gerschheimer, N. Nicolas, P. Nett et al., Effect of rivaroxaban on thrombin generation in vivo. A study in obese patients, Int J Lab Hematol, vol.40, pp.11-15, 2018.

A. Jabet, A. Stepanian, J. Golmard, C. Flaujac, B. S. Joly et al., Are screening tests reliable to rule out direct oral anticoagulant plasma levels at various thresholds (30, 50, or 100 ng/ml) in emergency situations?, Chest, vol.153, pp.288-290, 2018.

H. Brinkman, Global assays and the management of oral anticoagulation, Thromb J, vol.13, p.9, 2015.

C. Pailleret, G. Jourdi, V. Siguret, I. Gouin-thibault, S. Gandrille et al., Detection of direct oral factor Xa inhibitors anticoagulants by modified rotational thromboelastometry, Eur. J. Anaesth, vol.36, pp.449-456, 2019.

G. T. Gerotziafas, I. Elalamy, F. Depasse, E. Perzborn, and M. M. Samama, In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban, J Thromb Haemost, vol.5, pp.886-894, 2007.

M. M. Samama, J. Mendell, C. Guinet, L. Flem, L. Kunitada et al., In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux, Thromb Res, vol.129, pp.77-82, 2012.

S. Bloemen and H. C. Hemker, Al Dieri R. Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation, Haematologica, vol.98, pp.549-54, 2013.

Y. Morishima and C. Kamisato, Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay, Am J Clin Pathol, vol.143, pp.241-248, 2015.

R. Kremers, R. J. Wagenvoord, and H. C. Hemker, Comment on the use of computational models to study the effect of apixaban and rivaroxaban on thrombin generation, Thromb Haemost, vol.115, pp.869-70, 2016.

A. Tripodi, L. Padovan, C. Veena, E. Scalambrino, S. Testa et al., How the direct oral anticoagulant apixaban affects thrombin generation parameters, Thromb Res, vol.135, pp.1186-90, 2015.

J. Kintigh, P. Monagle, and V. Ignjatovic, A review of commercially available thrombin generation assays, Res Pract Thromb Haemost, vol.2, pp.42-50, 2018.

H. C. Hemker, P. Giesen, A. Dieri, R. Regnault, V. De-smedt et al., Calibrated automated thrombin generation measurement in clotting plasma, Pathophysiol Haemost Thromb, vol.33, pp.4-15, 2003.

V. Siguret, G. Foulon-pinto, J. Abdoul, C. A. Lecompte, T. Gouin-thibault et al., Thrombin generation analysis with a new automated system (ST-Genesia): interseries performances during DRIVING study and comparison with CAT system. 64 th Annual Scientific and Standardization Committee meeting -ISTH, 2018.

M. Arus, N. Vilalta, L. Romero, I. Tirado, D. Llobet et al., Comparison between the standard thrombin generation method and the automated hrombin generation

J. Pinheiro, D. Bates, S. Debroy, D. Sarkar, and . Core, Team nlme: Linear and Nonlinear Mixed Effects Models, 2018.

. R-core-team, R: A language and environment for statistical computing. R Foundation for Statistical Computing, 2018.

J. Perrin, F. Depasse, and T. Lecompte, Large external quality assessment suvery on thrombin generation with CAT: further evidence for the usefulness of normalisation with an external reference plasma, Thromb Res, vol.136, pp.125-155, 2015.

J. Dinkelaar, P. J. Molenaar, M. Ninivaggi, B. De-laat, H. Brinkman et al., In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for rivaroxaban, J Thromb Haemost, vol.11, pp.1111-1119, 2013.

E. Perzborn, S. Heitmeier, U. Buetehorn, and V. Laux, Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo, J Thromb Haemost, vol.12, pp.1054-65, 2014.

R. Kremers, R. J. Wagenvoord, and H. C. Hemker, Comment on the use of computational models to study the effect of apixaban and rivaroxaban on thrombin generation, Thromb Haemost, vol.115, pp.869-70, 2016.

E. Ollier, P. Mazzocco, R. D. Kaloshi, G. Idbaih, A. Alentorn et al., Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model, Fundam Clin Pharmacol, vol.31, issue.3, pp.347-58, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01623733

A. Tripodi, V. Chantarangkul, and P. M. Mannucci, Acquired coagulation disorders: revisited using global coagulation/anticoagulation testing, Br J Haematol, vol.147, pp.77-82, 2009.

S. Narouze, H. T. Benzon, D. A. Provenzano, A. Buvanendran, D. Andres et al., Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications: guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the

, American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain, Reg Anesth Pain Med, vol.40, pp.182-212, 2015.

P. Albaladejo, F. Bonhomme, N. Blais, J. P. Collet, D. Faraoni et al., Susen S; French Working Group on Perioperative Hemostasis (GIHP). Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: Updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP, Anaesth Crit Care Pain Med, vol.36, pp.73-76, 2015.

S. Bloemen, S. Zwaveling, T. Cate, H. , T. Cate-hoek et al., Prediction of bleeding risk in patients taking vitamin K antagonists using thrombin generation testing, PloS One, vol.12, p.176967, 2017.

H. Haidl, C. Cimenti, B. Leschnik, D. Zach, and W. Muntean, Age-dependency of thrombin generation measured by means of calibrated automated thrombography (CAT), Thromb Haemost, vol.95, pp.772-777, 2006.

H. C. Hemker, A. Dieri, and R. , Age-dependency of thrombin generation, Thromb Haemost, vol.95, pp.756-763, 2006.

M. A. Felmlee, M. E. Morris, and D. E. Mager, Mechanism-Based Pharmacodynamic Modeling, Computational Toxicology: Volume I, pp.583-600, 2012.

C. T. Ruff, R. P. Giugliano, E. Braunwald, D. A. Morrow, S. A. Murphy et al., Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial, Lancet, vol.385, pp.2288-95, 2015.